• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

    9/5/25 7:30:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IBIO alert in real time by email

    SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and provided a corporate update on its progress.

    "This fiscal year has been transformative for iBio as we advanced both our pipeline and corporate strategy," said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer of iBio. "We began building a differentiated preclinical portfolio in cardiometabolic diseases and obesity, highlighted by IBIO-610, an activin E-targeting antibody with compelling preclinical data supporting high-quality fat loss with muscle preservation, and IBIO-600, our long-acting anti-myostatin antibody. In parallel, we unveiled an additional innovative program, a bispecific antibody against myostatin and activin A, further expanding our next-generation antibody pipeline. Under our collaboration with AstralBio, we discovered a novel amylin receptor antibody. On the corporate side, our successful transfer of the listing of our common stock to Nasdaq, strengthened balance sheet, and the addition of successful industry leaders to our Board and management team have positioned iBio for long-term growth. And we are grateful our science was recently recognized by life sciences investors who participated in our recently closed offering to help us advance our innovative technologies. We remain committed to delivering transformative therapies to patients while driving sustainable value for our shareholders."

    Progress on Cardiometabolic and Obesity Pre-Clinical Pipeline:

    • Identified all four targets under the original multi-target discovery collaboration entered with AstralBio, Inc. ("AstralBio") in April 2024, focused on genetically validated pathways in obesity and cardiometabolic disease, and amended the collaboration agreement in April 2025 to add a fifth target.



    • In-licensed IBIO-600 and IBIO-610 from AstralBio, securing full development and commercialization rights to two of the company's most advanced assets.



    • Progressed IBIO-600, iBio's differentiated long-acting anti-myostatin antibody designed for subcutaneous administration, through a non-GLP non-human primate (NHP) pharmacokinetics (PK) study whose data demonstrated extended half-life and dose-dependent muscle growth.



    • Achieved development candidate nomination of IBIO-610, an activin E-targeting antibody, based on strong preclinical data from a 4-week study in diet-induced obese mice demonstrating a 26% reduction in fat mass and no measurable loss of lean mass. These findings demonstrate the potential of IBIO-610 for fat-selective weight loss.



    • iBio initiated an NHP study for IBIO-610 to evaluate pharmacokinetics and early signs of efficacy in obese and elderly NHPs, including its impact on fat and body composition.



    • Initiated a program leveraging iBio's Machine-Learning Antibody Engine to develop a bispecific antibody targeting myostatin and activin A, and aimed at weight loss promotion, muscle preservation, and weight regain prevention.



    • As part of iBio's collaboration with AstralBio, it unveiled and demonstrated in vivo proof-of-concept for an amylin receptor antibody program with potential to deliver quality weight loss, favorable gastrointestinal tolerability, and lean mass preservation. Studies in a mouse model of obesity demonstrated reduced acute food intake by 60% (p<0.05), comparable to the reduction in food intake from a clinically advanced dual amylin and calcitonin receptor agonist (DACRA) peptide (67%).



    Corporate Developments:

    • Began trading on the Nasdaq Stock Market under the ticker symbol "IBIO," marking a significant corporate milestone and enhancing visibility, improving trading liquidity, and aligning with the company's strategy to attract long-term institutional investors.



    • Raised $6.2 million in gross proceeds through a warrant inducement transaction with institutional investors, strengthening the company's balance sheet and providing additional working capital to support advancements in its pipeline.



    • Recently completed a $50 million underwritten public offering of pre-funded warrants and common warrants, with potential for an additional $50 million in gross proceeds upon full exercise of the common warrants, for total potential gross proceeds of up to $100 million.



    • Expanded the Board with biotech industry veterans, David Arkowitz and António Parada, who bring deep sector experience and proven leadership in capital markets and antibody discovery and development.



    • Bolstered the executive team with the hiring of Kristi Sarno, Senior Vice President of Business Development, to lead partnering efforts, drive pipeline growth, and accelerate external innovation.



    "In fiscal year 2025, we combined disciplined expense management with valuable funding initiatives to advance research and development of our obesity and cardiometabolic disease pipeline," said Felipe Duran, Chief Financial Officer of iBio. "We secured non-dilutive funding through collaboration revenue and a warrant inducement transaction, allowing us to enter fiscal year 2026 well-positioned to execute on our growth strategy and support development of our clinical drug candidates IBIO-600 and IBIO-610."

    Financial Results:

    Revenues for the fiscal year ended June 30, 2025, were approximately $0.4 million, an increase of $0.2 million over fiscal year 2024.

    Research and Development ("R&D") expenses for the fiscal year ended June 30, 2025, and June 30, 2024, were $8.3 million and $5.2 million, respectively, an increase of approximately $3.1 million. The increase in R&D expenses is mainly due to increased spending on consultants and outside services, and consumable supplies as a result of advancing research activities to support the company's IBIO-600, IBIO-610 and other preclinical pipeline assets.

    General and Administrative expenses for the fiscal year ended June 30, 2025, and June 30, 2024, were approximately $10.7 million and $11.7 million, respectively, a decrease of $1.0 million. The decrease is mainly attributable to a reduction in personnel-related costs, lower insurance premiums due to negotiated rates, and a decrease in depreciation, partially a reduction in legal fees, offset by increased franchise taxes and travel expenses.

    iBio held cash, cash equivalents and restricted cash of $8.8 million as of June 30, 2025.

    About iBio, Inc.

    iBio (Nasdaq: IBIO) is a cutting-edge biotech company leveraging AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases. By combining proprietary 3D modeling with innovative drug discovery platforms, iBio is creating a pipeline of breakthrough antibody treatments to address significant unmet medical needs. Our mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. For more information, visit www.ibioinc.com or follow us on LinkedIn.

    FORWARD-LOOKING STATEMENTS

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding iBio's ability to build a differentiated preclinical portfolio in cardiometabolic diseases and obesity; the potential of IBIO-610, an activin E-targeting antibody, to support high-quality fat loss with muscle preservation; the addition of successful industry leaders to the company's Board and management team positioning iBio for long-term growth; iBio's ability to drive sustainable value for its shareholders; iBio's Machine-Learning Antibody Engine program successfully developing a bispecific antibody targeting myostatin and activin A, aimed at weight loss promotion, muscle preservation, and weight regain prevention; the ability of iBio's in vivo proof-of-concept for an amylin receptor antibody program to deliver quality weight loss, favorable gastrointestinal tolerability, and lean mass preservation; the $6.2 million in gross proceeds from the warrant inducement transaction providing additional working capital to support advancements in its pipeline; the ability of Kristi Sarno, as Senior Vice President of Business Development, to lead partnering efforts, drive pipeline growth, and accelerate external innovation; the company's ability to advance research and development of its obesity and cardiometabolic disease pipeline; iBio being well-positioned to execute on its growth strategy and support development of its clinical drug candidates IBIO-600 and IBIO-610; the company's ability to leverage AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases; iBio's ability to combine its proprietary 3D modeling with its innovative drug discovery platforms to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; and iBio's ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the potential of IBIO-610, an activin E-targeting antibody, to support high-quality fat loss with muscle preservation; the ability of iBio's in vivo proof-of-concept for an amylin receptor antibody program to deliver quality weight loss, favorable gastrointestinal tolerability, and lean mass preservation; the company's ability to leverage AI and advanced computational biology to develop next-generation biopharmaceuticals for cardiometabolic diseases, obesity, cancer and other hard-to-treat diseases; iBio's ability to combine its proprietary 3D modeling with its innovative drug discovery platforms to create a pipeline of breakthrough antibody treatments to address significant unmet medical needs; iBio's ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio's ability to promote or commercialize its product candidates for specific indications; acceptance of iBio's product candidates in the marketplace and the successful development, marketing or sale of products; and whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio's filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2025 and its subsequent filings with the SEC on Forms 10-Q and 8-K. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

    Contact:

    iBio, Inc. 

    Investor Relations 

    [email protected] 

    Ignacio Guerrero-Ros, Ph.D., or David Schull

    Russo Partners, LLC

    [email protected]

    [email protected]

    (858) 717-2310 or (646) 942-5604

     
    iBio, Inc. and Subsidiaries

    Consolidated Statements of Operations

    (In Thousands, except per share amounts)
           
      Years Ended
      June 30, 
      2025     2024 
           
    Revenue $400  $225 
           
    Operating expenses:      
    Research and development  8,312   5,185 
    General and administrative  10,690   11,674 
    Total operating expenses  19,002   16,859 
           
    Operating loss  (18,602)  (16,634)
           
    Other income (expense):      
    Interest expense  (212)  (172)
    Interest income  437   363 
    Gain on sale of intellectual property  —   1,000 
    Total other income  225   1,191 
           
    Net loss from continuing operations  (18,377)  (15,443)
           
    Loss from discontinued operations  —   (9,464)
           
    Loss $(18,377) $(24,907)
           
    Loss per common share - basic and diluted - continuing operations $(1.75) $(4.03)
    Loss per common share - basic and diluted - discontinued operations $—  $(2.47)
    Loss per common share - basic and diluted - total $(1.75) $(6.50)
           
    Weighted-average common shares outstanding - basic and diluted  10,499   3,831 
           
    Share and per share data have been adjusted for June 30, 2024 presented to reflect the one-for-twenty (1:20) reverse stock split effective November 29, 2023.



    iBio, Inc. and Subsidiaries



    Consolidated Balance Sheets

    (In Thousands, except share and per share amounts)
           
      June 30,  June 30, 
      2025  2024 
         
    Assets      
    Current assets:      
    Cash and cash equivalents $8,582  $14,210 
    Subscription receivable  105   — 
    Promissory note receivable and accrued interest  —   713 
    Prepaid expenses and other current assets  1,034   749 
    Total Current Assets  9,721   15,672 
           
    Restricted cash  210   215 
    Promissory note receivable  1,098   1,081 
    Finance lease right-of-use assets, net of accumulated amortization  68   339 
    Operating lease right-of-use asset  2,051   2,401 
    Fixed assets, net of accumulated depreciation  3,163   3,632 
    Intangible assets, net of accumulated amortization  6,848   5,368 
    Security deposits  26   26 
    Total Assets $23,185  $28,734 
           
    Liabilities and Stockholders' Equity      
    Current liabilities:      
    Accounts payable $2,188  $358 
    Accrued expenses  1,345   2,028 
    Finance lease obligations - current portion  53   299 
    Operating lease obligation - current portion  490   436 
    Equipment financing payable - current portion  64   178 
    Term promissory note - current portion  766   218 
    Insurance premium financing payable  —   123 
    Contract liabilities  1,200   200 
    Total Current Liabilities  6,106   3,840 
           
    Finance lease obligations - net of current portion  —   53 
    Operating lease obligation - net of current portion  2,199   2,688 
    Equipment financing payable - net of current portion  —   63 
    Term promissory note - net of current portion  —   766 
    Total Liabilities  8,305   7,410 
           
    Stockholders' Equity      
    Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at June 30, 2025 and June 30, 2024; 0 shares issued and outstanding as of June 30, 2025 and June 30, 2024  —   — 
    Common Stock - $0.001 par value; 275,000,000 shares authorized at June 30, 2025 and June 30, 2024; 19,349,201 and 8,623,676 shares issued and outstanding as of June 30, 2025 and June 30, 2024, respectively  19   9 
    Additional paid-in capital  347,085   335,162 
    Accumulated deficit  (332,224)  (313,847)
    Total Stockholders' Equity  14,880   21,324 
    Total Liabilities and Stockholders' Equity $23,185  $28,734 
           
    Share and per share data have been adjusted for June 30, 2024 presented to reflect the one-for-twenty (1:20) reverse stock split effective November 29, 2023.


    Primary Logo

    Get the next $IBIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IBIO

    DatePrice TargetRatingAnalyst
    5/28/2024$5.00Buy
    Chardan Capital Markets
    11/29/2021$1.50Mkt Outperform
    JMP Securities
    11/29/2021$1.50Outperform
    JMP Securities
    More analyst ratings

    $IBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Duran Felipe bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 472% to 11,139 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:34:37 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Officer Brenner Martin bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 101% to 18,316 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:34:02 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Legal Officer Banjak Marc bought $25,000 worth of shares (9,191 units at $2.72), increasing direct ownership by 490% to 11,066 units (SEC Form 4)

    4 - iBio, Inc. (0001420720) (Issuer)

    1/13/25 4:33:31 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on iBio with a new price target

    Chardan Capital Markets initiated coverage of iBio with a rating of Buy and set a new price target of $5.00

    5/28/24 7:42:07 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on iBio with a new price target

    JMP Securities initiated coverage of iBio with a rating of Mkt Outperform and set a new price target of $1.50

    11/29/21 7:34:24 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JMP Securities initiated coverage on iBio with a new price target

    JMP Securities initiated coverage of iBio with a rating of Outperform and set a new price target of $1.50

    11/29/21 7:32:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

    SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and provided a corporate update on its progress. "This fiscal year has been transformative for iBio as we advanced both our pipeline and corporate strategy," said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer of iBio. "We began building a differentiated preclinical portfolio in cardiometabolic diseases and obesity, highlighted by IBIO-610, an activin E-targeting antibody with compelling preclinical data supporting high-quality fat loss with muscle pre

    9/5/25 7:30:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Announces Closing of $50 Million Public Offering

    Total gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised for cash Financing was led by Balyasny Asset Management and included participation from Cormorant Asset Management, Adage Capital Partners LP, Ally Bridge Group, Marshall Wace, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the closing of its previously announced underwritten public offering of the securities described below for initial gross proceeds of approximately $50 million, before deducting underwr

    8/25/25 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Announces Pricing of $50 Million Public Offering

    SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the "offering") of (i) pre-funded warrants to purchase 71,540,000 shares of iBio's common stock (the "pre-funded warrants"), and (ii) accompanying Series G warrants representing the right to purchase (the "Series G warrants") (a) 35,770,000 shares of iBio's common stock, or pre-funded warrants in lieu thereof, and (b) Series H warrants representing the right to purchase 35,770,000 shares of iBio's common stock, or pre-funded warrants in lieu thereof (the "Series H warrants"). The combined public offeri

    8/19/25 8:01:18 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Legal Officer Banjak Marc

    4 - iBio, Inc. (0001420720) (Issuer)

    2/24/25 6:01:30 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Duran Felipe

    4 - iBio, Inc. (0001420720) (Issuer)

    2/24/25 6:00:59 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Officer Brenner Martin

    4 - iBio, Inc. (0001420720) (Issuer)

    2/24/25 6:00:12 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    SEC Filings

    View All

    SEC Form 10-K filed by iBio Inc.

    10-K - iBio, Inc. (0001420720) (Filer)

    9/5/25 9:30:30 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - iBio, Inc. (0001420720) (Filer)

    9/5/25 9:00:29 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - iBio, Inc. (0001420720) (Filer)

    8/21/25 4:11:41 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Leadership Updates

    Live Leadership Updates

    View All

    iBio to Begin Trading on the Nasdaq Stock Exchange

    SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company on Mar 4, 2025, and will continue to trade under the symbol "IBIO." The Company's common stock will continue to trade on the NYSE American until the market close on Mar 3, 2025. Martin Brenner, Ph.D., DVM, iBio's CEO and Chief Scientific Officer, commented, "We are pleased to announce our listing on the Nas

    2/19/25 4:05:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Strengthens Board with Appointment of Two New Independent Directors

    SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and António Parada to its Board of Directors adding key experience in finance, leadership and antibody discovery. "These appointments expand and strengthen our board to align with iBio's vision of becoming a next-generation antibody discovery and development company with a robust clinical pipeline of therapeutic antibodies for cardiometabolic diseases and oncology. As a seasoned CFO, David brings extensive financial experience and industry relationships that will benefit iBio as we

    11/25/24 8:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Reports Fiscal First Quarter 2025 Financial Results

    SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. "In our fiscal first quarter we advanced our collaboration with AstralBio, manufacturing and dosing a lead molecule with therapeutic potential for muscle wasting and obesity in non-human primate in vivo studies and progressing early work on additional targets. We strengthened our leadership team by hiring a seasoned business development executive, Kristi Sarno—a move essential to our efforts to critically enable new partners in antibody development for challenging targets," said CEO and

    11/12/24 4:05:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Financials

    Live finance-specific insights

    View All

    iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

    Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of antibody-based agonists to address the growing demand for safer, longer-acting treatments for obesity and cardiometabolic diseases Conference call today, June 24 at 8:30 a.m. ET to discuss new pre-clinical data and obesity pipeline SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of next-generation antibody therapies, today announced preclinical data in which an engineered amylin receptor agonist antibody reduced acute food intake

    6/24/25 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

    Review of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the Company will host a conference call on Tuesday, June 24, at 8:30 a.m. ET to review its latest advances in obesity and cardiometabolic disease treatments and announce a third target in the AstralBio Collaboration in addition to Myostatin and Activin E.Martin Brenner, DVM, Ph.D., iBio's CEO and Chief Scientific Officer, will outline how iBio is pioneering the next generation of antibo

    6/23/25 4:15:00 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

    – Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets – – Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration – – Company to host webcasted conference call today at 8:30 a.m. EDT to discuss AstralBio collaboration – BRYAN, Texas and SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company") announces today that it has entered into a collaboration agreement with AstralBio,

    3/27/24 7:00:00 AM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $IBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by iBio Inc.

    SC 13G - iBio, Inc. (0001420720) (Subject)

    11/14/24 8:47:49 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by iBio Inc.

    SC 13G/A - iBio, Inc. (0001420720) (Subject)

    11/14/24 4:48:52 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by iBio Inc. (Amendment)

    SC 13G/A - iBio, Inc. (0001420720) (Subject)

    4/9/24 5:22:43 PM ET
    $IBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care